Obtain mechanistic understanding and novel insights into disease biology.
Speed up your early R&D process and reduce your time-to-decision making.
Identify targets and lead compounds with potential to produce first-in-class medicines.
An approach you can trust
We are seasoned specialists in providing neurobiology research services. Our mission is to create groundbreaking in vitro concepts that will advance the neuroscience research field and enable our Clients to conduct successful drug discovery programs.
From dechipering disease mechanisms to exploration of novel assay concepts.
Using functional genomics and advanced in vitro models we help our Clients to identify and validate novel targets.
Phenotypic and target-based assay development, screening and lead optimization.
Elevated neurobiology in vitro research
What sets us apart from the competition is our unique discovery platform. By combining drug discovery expertise and disease area knowledge with cutting-edge technologies, we are creating complex disease models and assays for functional and morphological screening.
News and events
Latest news and insights
Cellectricon values scientific exchange and we invite you to take part of our latest news and to learn about upcoming events.
Discovery Europe 2023
Discovery Europe and the Neuroscience Drug Development Europe meetings take place in parallel in Berlin, Germany on June 6-7, 2023....
The Neuro4D conference takes place in Mainz, Germany on May 15-16, 2023. With a focus on drug discovery for proteopathic...
Delix Therapeutics partners with Cellectricon, Expressive Neuroscience and expands science team to accelerate drug discovery and translatability
We’re excited to be working with Delix Therapeutics and support their development of neuroplasticity-promoting therapeutics! At Cellectricon, we solve our...
The AD/PD 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders takes place in Gothenburg, Sweden on...
Cellectricon strengthens IP portfolio – Receives “Intention to Grant” from the European Patent Office
Cellectricon AB, a leading provider of neurobiology in vitro research services, today announced that the company received notice of intention...
The Neuroscience 2022 meeeting takes place in San Diego on November 12-16. During the conference, we will present several posters...
Webcast - Validation of an in vitro α-synuclein aggregation assay for target discovery in neurodegenerative disease research
Event info: In this webcast, Paul Karila, Head of Drug Discovery, and Johan Pihl, Chief Operating Officer, discuss the development...
Poster presentation at Advances in Cell-based Screening meeting
Missed Cellectricon at the ELRIG meeting on Advances in Cell-based Screening? There is still a chance to receive a copy...